Claims for Patent: 9,675,616
✉ Email this page to a colleague
Summary for Patent: 9,675,616
Title: | Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-C]quinolines |
Abstract: | The present invention relates to substituted phenoxypyridine compounds of general formula (I); in which R1, R2 and R3 are as defined in the claims, to methods of preparing said compounds, to intermediates for the preparation of said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. ##STR00001## |
Inventor(s): | Scott; William Johnston (Guilford, CT), Petrov; Orlin (Berlin, DE), Mowes; Manfred (Berlin, DE), Liu; Ningshu (Berlin, DE), Bomer; Ulf (Glienicke, DE) |
Assignee: | BAYER INTELLECTUAL PROPERTY GMBH (Monheim, DE) |
Application Number: | 13/884,125 |
Patent Claims: | 1. A compound of formula (I): ##STR00058## wherein: R.sup.1 is --(CH.sub.2).sub.n--(CHR.sup.4)--(CHR.sup.4)--(CH.sub.2).sub.m--N(R.sup.5- )(R.sup.5'); R.sup.2 is a
heteroaryl of structure: ##STR00059## optionally substituted with 1, 2 or 3 R.sup.6 groups, wherein: * indicates the point of attachment of said heteroaryl with the rest of the structure of formula (I), X is N or C--R.sup.6, and X' is O, S, NH,
N--R.sup.6, N or C--R.sup.6, with the proviso that when X and X' are both C--R.sup.6, then one C--R.sup.6 is C--H; R.sup.3 is methyl; R.sup.4 is hydroxy; R.sup.5 is a hydrogen atom, C.sub.1-C.sub.6-alkyl,
C.sub.3-C.sub.6-cycloalkyl-C.sub.1-C.sub.6-alkyl, aryl-C.sub.1-C.sub.6-alkyl or C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl, wherein said aryl-C.sub.1-C.sub.6-alkyl group is substituted, one or more times, in the same way or differently, with R.sup.6;
R.sup.5' is aryl-C.sub.1-C.sub.6-alkyl, wherein said aryl-C.sub.1-C.sub.6-alkyl group is substituted, one or more times, in the same way or differently, with R.sup.6; each occurrence of R.sup.6 is the same or different and is independently a hydrogen
atom, a halogen atom, C.sub.1-C.sub.6-alkyl, C.sub.2-C.sub.6-alkenyl, C.sub.2-C.sub.6-alkynyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyl-C.sub.1-C.sub.6-alkyl, aryl, aryl-C.sub.1-C.sub.6-alkyl, heteroaryl, heteroaryl-C.sub.1-C.sub.6-alkyl,
3- to 8-membered heterocyclic ring, 3- to 8-membered heterocyclyl-C.sub.1-C.sub.6-alkyl, --C.sub.1-C.sub.6-alkyl-OR.sup.7, --C.sub.1-C.sub.6-alkyl-SR.sup.7, --C.sub.1-C.sub.6-alkyl-N(R.sup.7)(R.sup.7'), --C.sub.1-C.sub.6-alkyl-C(.dbd.O)R.sup.7, --CN,
--C(.dbd.O)OR.sup.7, --C(.dbd.O)N(R.sup.7)(R.sup.7'), --OR.sup.7, --SR.sup.7, --N(R.sup.7)(R.sup.7'), or --NR.sup.7C(.dbd.O)R.sup.7, each of which is optionally substituted with 1 or more R.sup.8 groups; each occurrence of R.sup.7 and R.sup.7' is the
same or different and is independently a hydrogen atom, C.sub.1-C.sub.6-alkyl, C.sub.2-C.sub.6-alkenyl, C.sub.2-C.sub.6-alkynyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyl-C.sub.1-C.sub.6-alklyl, C.sub.3-C.sub.6-cycloalkenyl, aryl,
aryl-C.sub.1-C.sub.6-alkyl, heteroaryl, 3- to 8-membered heterocyclic ring, 3- to 8-membered heterocyclyl-C.sub.1-C.sub.6-alkyl, or heteroaryl-C.sub.1-C.sub.6-alkyl; each occurrence of R.sup.8 is independently a halogen atom, nitro, hydroxy, cyano,
formyl, acetyl, amino, C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-alkoxy, C.sub.2-C.sub.6-alkenyl, C.sub.2-C.sub.6-alkynyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyl-C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-cycloalkenyl, aryl,
aryl-C.sub.1-C.sub.6-alkyl, heteroaryl, 3- to 8-membered heterocyclic ring, heterocyclyl-C.sub.1-C.sub.6-alkyl, or heteroaryl-C.sub.1-C.sub.6-alkyl; and n is an integer of 1 and m is an integer of 1, or a stereoisomer, a tautomer, an N-oxide, a hydrate,
a solvate, or a physiologically acceptable salt thereof, or a mixture of any of the foregoing.
2. The compound according to claim 1, wherein: R.sup.1 is --(CH.sub.2).sub.n--(CHR.sup.4)--(CH.sub.2).sub.m--N(R.sup.5)(R.sup.5'); R.sup.2 is a heteroaryl of structure: ##STR00060## wherein: * indicates the point of attachment of said heteroaryl with the rest of the structure of formula (I); R.sup.3 is methyl; R.sup.4 is hydroxy; R.sup.5 is a hydrogen atom, C.sub.1-C.sub.6-alkyl, aryl-C.sub.1-C.sub.6-alkyl or C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl, wherein said aryl-C.sub.1-C.sub.6-alkyl group is substituted, one or more times, in the same way or differently, with R.sup.6; R.sup.5' is aryl-C.sub.1-C.sub.6-alkyl, wherein said aryl-C.sub.1-C.sub.6-alkyl group is substituted, one or more times, in the same way or differently, with R.sup.6; each occurrence of R.sup.6 is the same or different and is independently a hydrogen atom or a methyl group; each occurrence of R.sup.7 and R.sup.7' is the same or different and is independently a hydrogen atom, C.sub.1-C.sub.6-alkyl, C.sub.2-C.sub.6-alkenyl, C.sub.2-C.sub.6-alkynyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyl-C.sub.1-C.sub.6-alklyl, C.sub.3-C.sub.6-cycloalkenyl, aryl, aryl-C.sub.1-C.sub.6-alkyl, heteroaryl, 3- to 8-membered heterocyclic ring, 3- to 8-membered heterocyclyl-C.sub.1-C.sub.6-alkyl, or heteroaryl-C.sub.1-C.sub.6-alkyl; each occurrence of R.sup.8 is independently a halogen atom, nitro, hydroxy, cyano, formyl, acetyl, amino, C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-alkoxy, C.sub.2-C.sub.6-alkenyl, C.sub.2-C.sub.6-alkynyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyl-C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-cycloalkenyl, aryl, aryl-C.sub.1-C.sub.6-alkyl, heteroaryl, 3- to 8-membered heterocyclic ring, heterocyclyl-C.sub.1-C.sub.6-alkyl, or heteroaryl-C.sub.1-C.sub.6-alkyl; and n is an integer of 1 and m is an integer of 1, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a physiologically acceptable salt thereof, or a mixture of any of the foregoing. 3. The compound according to claim 1, wherein: R.sup.1 is --(CH.sub.2).sub.n--(CHR.sup.4)--(CH.sub.2).sub.m--N(R.sup.5)(R.sup.5); R.sup.2 is a heteroaryl of structure: ##STR00061## wherein: * indicates the point of attachment of said heteroaryl with the rest of the structure of formula (I); R.sup.3 is methyl; R.sup.4 is hydroxy; R.sup.5 is a hydrogen atom, C.sub.1-C.sub.6-alkyl, C.sub.3-C.sub.6-cycloalkyl-C.sub.1-C.sub.6-alkyl, aryl-C.sub.1-C.sub.6-alkyl or C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl, wherein said aryl-C.sub.1-C.sub.6-alkyl group is substituted, one or more times, in the same way or differently, with R.sup.6; R.sup.5' is aryl-C.sub.1-C.sub.6-alkyl, wherein said aryl-C.sub.1-C.sub.6-alkyl group is substituted, one or more times, in the same way or differently, with R.sup.6; each occurrence of R.sup.6 is the same or different and is independently a hydrogen atom or a methyl group; each occurrence of R.sup.7 and R.sup.7' is the same or different and is independently a hydrogen atom, C.sub.1-C.sub.6-alkyl, C.sub.2-C.sub.6-alkenyl, C.sub.2-C.sub.6-alkynyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyl-C.sub.1-C.sub.6-alklyl, C.sub.3-C.sub.6-cycloalkenyl, aryl, aryl-C.sub.1-C.sub.6-alkyl, heteroaryl, 3- to 8-membered heterocyclic ring, 3- to 8-membered heterocyclyl-C.sub.1-C.sub.6-alkyl, or heteroaryl-C.sub.1-C.sub.6-alkyl; each occurrence of R.sup.8 is independently a halogen atom, nitro, hydroxy, cyano, formyl, acetyl, amino, C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-alkoxy, C.sub.2-C.sub.6-alkenyl, C.sub.2-C.sub.6-alkynyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyl-C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-cycloalkenyl, aryl, aryl-C.sub.1-C.sub.6-alkyl, heteroaryl, 3- to 8-membered heterocyclic ring, heterocyclyl-C.sub.1-C.sub.6-alkyl, or heteroaryl-C.sub.1-C.sub.6-alkyl; and n is an integer of 1 and m is an integer of 1, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a physiologically acceptable salt thereof, or a mixture of any of the foregoing. 4. The compound according to claim 1, wherein: R.sup.1 is --(CH.sub.2).sub.n--(CHR.sup.4)--(CH.sub.2).sub.m--N(R.sup.5)(R.sup.5'); R.sup.2 is a heteroaryl of structure: ##STR00062## wherein: * indicates the point of attachment of said heteroaryl with the rest of the structure of formula (I), and Z is N or C--R.sup.6; R.sup.3 is methyl; R.sup.4 is hydroxy; R.sup.5 is a hydrogen atom, C.sub.1-C.sub.6-alkyl, C.sub.3-C.sub.6-cycloalkyl-C.sub.1-C.sub.6-alkyl, aryl-C.sub.1-C.sub.6-alkyl or C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl, wherein said aryl-C.sub.1-C.sub.6-alkyl group is substituted, one or more times, in the same way or differently, with R.sup.6; R.sup.5' is aryl-C.sub.1-C.sub.6-alkyl, wherein said aryl-C.sub.1-C.sub.6-alkyl group is substituted, one or more times, in the same way or differently, with R.sup.6; each occurrence of R.sup.6 is the same or different and is independently a hydrogen atom or a methyl group; each occurrence of R.sup.7 and R.sup.7' is the same or different and is independently a hydrogen atom, C.sub.1-C.sub.6-alkyl, C.sub.2-C.sub.6-alkenyl, C.sub.2-C.sub.6-alkynyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyl-C.sub.1-C.sub.6-alklyl, C.sub.3-C.sub.6-cycloalkenyl, aryl, aryl-C.sub.1-C.sub.6-alkyl, heteroaryl, 3- to 8-membered heterocyclic ring, 3- to 8-membered heterocyclyl-C.sub.1-C.sub.6-alkyl, or heteroaryl-C.sub.1-C.sub.6-alkyl; each occurrence of R.sup.8 is independently a halogen atom, nitro, hydroxy, cyano, formyl, acetyl, amino, C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-alkoxy, C.sub.2-C.sub.6-alkenyl, C.sub.2-C.sub.6-alkynyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyl-C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-cycloalkenyl, aryl, aryl-C.sub.1-C.sub.6-alkyl, heteroaryl, 3- to 8-membered heterocyclic ring, heterocyclyl-C.sub.1-C.sub.6-alkyl, or heteroaryl-C.sub.1-C.sub.6-alkyl; and n is an integer of 1 and m is an integer of 1, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a physiologically acceptable salt thereof, or a mixture of any of the foregoing. 5. The compound according to claim 1, wherein: R.sup.1 is --(CH.sub.2).sub.n--(CHR.sup.4)--(CH.sub.2).sub.m--N(R.sup.5)(R.sup.5'); R.sup.2 is a heteroaryl of structure: ##STR00063## wherein: * indicates the point of attachment of said heteroaryl with the rest of the structure of formula (I), and Z is N or C--R.sup.6; R.sup.3 is methyl; R.sup.4 is hydroxy; R.sup.5 is a hydrogen atom, C.sub.1-C.sub.6-alkyl, C.sub.3-C.sub.6-cycloalkyl-C.sub.1-C.sub.6-alkyl, aryl-C.sub.1-C.sub.6-alkyl or C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl, wherein said aryl-C.sub.1-C.sub.6-alkyl group is substituted, one or more times, in the same way or differently, with R.sup.6; R.sup.5' is aryl-C.sub.1-C.sub.6-alkyl, wherein said aryl-C.sub.1-C.sub.6-alkyl group is substituted, one or more times, in the same way or differently, with R.sup.6; each occurrence of R.sup.6 is the same or different and is independently a hydrogen atom or a methyl group; each occurrence of R.sup.7 and R.sup.7' is the same or different and is independently a hydrogen atom, C.sub.1-C.sub.6-alkyl, C.sub.2-C.sub.6-alkenyl, C.sub.2-C.sub.6-alkynyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyl-C.sub.1-C.sub.6-alklyl, C.sub.3-C.sub.6-cycloalkenyl, aryl, aryl-C.sub.1-C.sub.6-alkyl, heteroaryl, 3- to 8-membered heterocyclic ring, 3- to 8-membered heterocyclyl-C.sub.1-C.sub.6-alkyl, or heteroaryl-C.sub.1-C.sub.6-alkyl; each occurrence of R.sup.8 is independently a halogen atom, nitro, hydroxy, cyano, formyl, acetyl, amino, C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-alkoxy, C.sub.2-C.sub.6-alkenyl, C.sub.2-C.sub.6-alkynyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6 cycloalkyl C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-cycloalkenyl, aryl, aryl-C.sub.1-C.sub.6-alkyl, heteroaryl, 3- to 8-membered heterocyclic ring, heterocyclyl-C.sub.1-C.sub.6-alkyl, or heteroaryl-C.sub.1-C.sub.6-alkyl; and n is an integer of 1 and m is an integer of 1, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a physiologically acceptable salt thereof, or a mixture of any of the foregoing. 6. The compound according to claim 1, which is selected from the group consisting of: rel-2-Amino-N-(8-{[(2R)-2-hydroxy-3-{[(1R)-1-phenylethyl]amino}propyl]oxy- }-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carboxam- ide; 2-Amino-N-(8-{[(2S)-2-hydroxy-3-{[(1S)-1-phenylethyl]amino}propyl]oxy- }-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carboxam- ide; and 2-Amino-N-(8-{[(2R)-2-hydroxy-3-{[(1S)-1-phenylethyl]amino}propyl- ]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carb- oxamide, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a physiologically acceptable salt thereof, or a mixture of any of the foregoing. 7. A method of preparing the compound of formula (I) according to claim 1, said method comprising the step of reacting an intermediate compound of formula (XI): ##STR00064## wherein R1 and R3 are as defined in claim 1, with a compound of formula (XIa): R.sup.2COOH (XIa), wherein R2 is as defined in claim 1, to give the compound of formula (I): ##STR00065## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined in claim 1. 8. A pharmaceutical composition comprising the compound of formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of any of the foregoing, according to claim 1, and a pharmaceutically acceptable diluent or carrier. 9. A pharmaceutical combination comprising: one or more compounds of formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of any of the foregoing, according to claim 1; and one or more agents selected from: a taxane, Docetaxel, Paclitaxel, or Taxol; an epothilone, Ixabepilone, Patupilone, or Sagopilone; Mitoxantrone; Predinisolone; Dexamethasone; Estramustin; Vinblastin; Vincristin; Doxorubicin; Adriamycin; Idarubicin; Daunorubicin; Bleomycin; Etoposide; Cyclophosphamide; Ifosfamide; Procarbazine; Melphalan; 5-Fluorouracil; Capecitabine; Fludarabine; Cytarabine; Ara-C; 2-Chloro-2'-deoxyadenosine; Thioguanine; an anti-androgen, Flutamide, Cyproterone acetate, or Bicalutamide; Bortezomib; a platinum derivative, Cisplatin, Carboplatin; Chlorambucil; Methotrexate; and Rituximab. 10. A method for treatment of a haemotological tumour, solid tumour or metastases thereof selected from leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours, brain tumours and brain metastases, tumours of the thorax, non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours, renal, bladder and prostate tumours, skin tumours, and sarcomas, and metastases thereof, comprising administering to a human or animal in need thereof a pharmaceutically effective amount of the compound of formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of any of the foregoing, according to claim 1. 11. A compound of formula (XI): ##STR00066## wherein R1 and R3 are as defined in claim 1. |
Details for Patent 9,675,616
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2030-11-11 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2030-11-11 |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | ⤷ Try a Trial | 2030-11-11 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.